Optimize cost efficiency
Industry challenges
The penetration of generic and the end of patent’s protection for major blockbusters (65 billion off patent by 2012)* urges cost reduction & strengthening of the pipeline. The pressure on costs will induce the implementation of a new organizational model characterized by more analytical and value adding activities and a higher level of shared processes.
The frequency & diversity of governmental interventions increases difficulty to predict future earnings and require increased strategic flexibility.
The import/export patterns and the counterfeiting urges the review of the traditional supply chain model.
In order to face these industry challenges, most companies will need to answer the following key questions:
Key questions: How can we optimize...
- Financial services (Target operating model, shared services)
- Performance management (costing model, planning, dashboard,…)
- Our working capital
- Our supply chain offering
- Clinical development costs (Investigators, patients insurances, safety, regulations)
- Infrastructure
Deloitte offering - selected approaches & credentials
Deloitte has helped several big Life Sciences companies in:
- Building shared service centers
- Conducting adding value benchmarking analysis.
- Financial Organisational Review / Shared Services
- Financial Process Review
- Outsourcing Advisory
- Dashboard implementation
- BI Implementation
- Planning Budgeting and Forecasting
- Activity Based Costing
*82 billion in sales is at risk through 2014 (source: datamonitor)
Material on this website is © 2012 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.